Market Intelligence, Clinical Progress, and High-Purity Reagents for HIV Prevention, Oncology Metastasis, and Immunology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCR5/CD195 drug discovery:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD) | CCR5 N-terminal ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View CCR5 Products |
| Gene Delivery | CCR5 Full-Length Lentivirus Particles Premade particles for stable cell line generation. Preserves native GPCR conformation (7-TM). |
View CCR5 Products |
| Mutant Control | CCR5-Δ32 (Delta32) Mutant Lentivirus Natural HIV-resistance variant. Critical for specificity and off-target screening. |
View CCR5 Products |
| Benchmark Ab | Anti-CCR5 (Leronlimab/PRO 140 Biosimilar) Recombinant positive control for receptor occupancy assays. |
View CCR5 Products |
| Validator | CCR5 siRNA Set For knockdown verification and specificity controls. |
View CCR5 Products |
| Related Target: CCR2 | CCR2 (Chemokine Receptor 2) Subfamily counter-screening target; shares CCL2 binding profile. |
View CCR2 Products |
| Related Target: CXCR4 | CXCR4 (CD184) Alternative HIV co-receptor; metastasis pathway partner. |
View CXCR4 Products |
| Related Target: CD4 | CD4 (HIV Receptor) Primary HIV binding partner; essential for co-receptor assays. |
View CD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation (7-TM integrity) | Lentivirus-mediated stable cell lines; preserves native membrane topology and signaling competence |
| Cross-species Cyno/Mouse/Human eval | Ortholog proteins available with >95% purity; sequence identity verified by mass spec |
| Allosteric vs Orthosteric Binding Discrimination | WT CCR5 vs Δ32 Mutant pair for differential binding validation |
| Internalization & Trafficking (ADC/Degrader) | Cell-based lentivirus system with high surface expression for flow cytometry/internalization assays |
| Off-target Specificity (Chemokine Receptor Family) | CCR2/CXCR4/CD4 homolog cell lines and validated siRNA for selectivity confirmation |
| Lack of Controls | Clinical Benchmark Antibodies (Leronlimab class) and validated siRNA included |
Live CCR5/CD195 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCR5 therapeutics is transitioning from acute HIV treatment toward functional cure strategies, immuno-oncology, and autoimmune indications. As first-generation small molecules (Maraviroc) face generic competition, the next wave of R&D targets long-acting biologics, CCR5-knockout cell therapies, and tumor microenvironment modulation. The emergence of CCR5 antagonists in metastatic breast cancer and colon cancer represents a significant indication expansion beyond infectious disease into oncology, NASH, and graft-versus-host disease (GvHD). Gene-editing approaches targeting the CCR5Δ32 phenotype continue to advance in early-phase cell therapy, signaling a durable-cure paradigm.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | ViiV Healthcare (Maraviroc), Pfizer | HIV-1 Infection, Inflammation | Allosteric Binding Assay & Calcium Flux (Need high-purity WT vs Δ32 mutants; stable cell lines for signaling) |
| Monoclonal Antibody | CytoDyn (Leronlimab/PRO 140) | HIV, Metastatic Cancer, NASH | Receptor Occupancy & Internalization Assay (Need stable cell lines for conformational binding) |
| Gene / Cell Therapy | CRISPR Therapeutics, Calimmune, Sangamo Therapeutics | HIV Functional Cure | Knockout Validation (Need Δ32 reference standards and anti-CCR5 benchmark antibodies) |
| CAR-T / Cell Therapy | Multiple Academic Groups | Oncology (CCR5+ tumors) | Cytotoxicity & Specificity Panel (Need CCR2/CXCR4 counter-screening) |
| Bispecific / Biologic | Preclinical / Academic | Oncology, Autoimmune | Heterodimer validation and cross-reactivity panel (Need CCR2/CXCR4 homolog cell lines) |